Avalia - Treatment Therapy for HPV-associated Cancers
Avalia’s patented chemical design lends itself well to the treatment of HPV-associated cancers. Certain strains of HPV are responsible for the onset of cervical cancer, many anogenital cancers and head and neck cancer. Avalia’s preclinical program has shown significantly increased survival rates and cures in models of HPV-associated cancer in combination with approved therapeutic agents and other therapies in development.
-
Most popular related searches
Details
Each year, more than 2 million cancer cases are attributed to 10 different infectious agents. Seven of these are viruses, including human papillomavirus (HPV), hepatitis B and C viruses and the Epstein-Barr virus. Although several vaccines have been developed to protect individuals from the onset of cancer from these viral infections, these are only affective if received prior to exposure to the virus.
Avalia’s discovery and preclinical program is focused on developing cancer immunotherapies for those patients that have developed virus-associated cancers.
Customer reviews
No reviews were found for Avalia - Treatment Therapy for HPV-associated Cancers. Be the first to review!